Optimi is a commercial-stage pharmaceutical company manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. $OPTH
Currently in Canada we're growing the mushrooms, we're extracting the psilocybin, and shipping it across the world, but our physicians can't prescribe it. This makes no sense at all!
Please sign my petition supporting Thomas' Bill: thomasbill.ca/petition
Optimi Health Chairman of the Board, JJ Wilson, comments on the company's 2027 clinical plan and potential U.S. FDA pathway. For more information, visit: bit.ly/4kWKNQm$OPTH
Optimi has provided an update on its clinical programs, commercial supply & Ibogaine Initiative. The proposed OPTI-101 protocol amendment would convert the Ph 2 trial into a randomized, double-blind Ph 2b for severe MDD w/ dosing expected in Q1 2027 bit.ly/4kWKNQm$OPTH
A heartfelt thank you to everyone who took part in the first annual Psilocybin Summit.
It was a distinct honour to hear the powerful personal stories of recovery, the moving testimonials, the exciting advancements in science, and the hope for a better future.
I'm especially grateful to those who travelled great distances to be part of this important conversation.
The new friendships, partnerships, and allies gained for Thomas's Bill are truly inspiring.
Thank you to everyone who shared their stories, their knowledge, and their hope. We're building something special, and we're just getting started.
#thomasbill#psilocybinsummit
Researchers are optimistic about psychedelic drugs as potential treatments for depression and mood disorders, despite pushback having stalled the field
go.nature.com/4e1WDEM
Quality systems extend throughout the facility.
Organized workspaces and documented workflows help manufacturing teams maintain oversight across day-to-day operations.
“There is something in common with what we're seeing about the impact of these different mechanisms where we are seeing benefit in these studies, and they do all have some change in perception.”
Carole Ho, Executive Vice President and President, Eli Lilly and Lilly Neuroscience, speaking at The Psychedelic Healthcare Forum.
When discussing the role of the subjective experience, or ‘trip’, in psychedelic therapies.
A look inside Optimi’s production process in Princeton, British Columbia.
Maintaining control from botanical starting material through finished dosage form manufacturing supports consistency across the regulated programs we serve.
Researchers are optimistic about psychedelic drugs as potential treatments for depression and mood disorders, despite pushback having stalled the field
go.nature.com/4iH8B9o
Two years ago the FDA rejected the first psychedelic therapy for PTSD. Today the US government is openly asking how it can get these treatments to millions of veterans as quickly as possible.
That is a remarkable shift, and in my view it is not mainly about politics. It is about the fact that conventional psychiatry has very little to offer people with severe PTSD or treatment-resistant depression. Many veterans did not wait for Washington. They travelled to Mexico, got treated and came back with stories that were impossible to ignore.
The brain is the last great frontier in medicine. Psychedelics are one of the first tools that actually change how it works, rather than just managing symptoms.
Article in the comments.
Optimi Health CEO and Co-Founder Dane Stevens comments on the establishment of Optimi Australia, a new wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across the country. For details: bit.ly/4jHuV3Q$OPTH
Optimi Health announced the establishment of Optimi Australia Pty Ltd, a wholly owned subsidiary responsible for distribution and business development in Australia, and the appointment of Adrian Jones as Director of Australian Operations. bit.ly/4jHuV3Q$OPTH
Since President Trump's psychedelics-focused Executive Order in April, a slew of federal agencies and departments have engaged in related activities: from funding psychedelic research through to public hearings and requests for information.
Producing botanical psilocybin for regulated programs requires control across cultivation, processing, testing and finished dosage form manufacturing.
Optimi manages these stages at its Princeton facility to support consistency and quality throughout the process.
New episode: Peaking director Jordan Kronick on taking cameras into the dosing room across six psychedelics, the 2004 doc that helped reopen MDMA research, and psychedelics for brain injury in pro sports.
bit.ly/pt662-peaking
$OPTH CEO Dane Stevens comments on the completion of the Company's latest MDMA finished drug product batch, expected to supply the proposed Phase 3 PTSD trial in Canada, a planned 2026 export to Australia, & a previously announced trial in Israel with MAPS. bit.ly/4ie9Xap